CRYOFOCUS-B (06922): Anti-Gastroesophageal Reflux System Receives NMPA Approval

Stock News

2025/12/16

CRYOFOCUS-B (06922) announced that on December 15, 2025, its anti-gastroesophageal reflux system, consisting of an implantable anti-reflux device and an esophageal measurement tool, has obtained approval from the National Medical Products Administration (NMPA). With the approval of this system, the company's product portfolio has become more comprehensive and diversified.

The anti-gastroesophageal reflux system is a self-developed surgical device designed for magnetic sphincter augmentation (MSA) procedures to treat gastroesophageal reflux disease (GERD). The MSA procedure aims to enhance the tension of the lower esophageal sphincter (LES) to achieve anti-reflux effects.

The system works by implanting a device in the functional region of the LES outside the esophagus. The magnetic beads within the implanted device generate magnetic attraction, thereby strengthening the LES tension and restoring its anti-reflux function to treat GERD.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1121699847"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121699847\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121699847?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 18:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121699847","market":"sg","top_or_hot":-1,"title":"CRYOFOCUS-B (06922): Anti-Gastroesophageal Reflux System Receives NMPA Approval","media":"Stock News","content":"<p>CRYOFOCUS-B (06922) announced that on December 15, 2025, its anti-gastroesophageal reflux system, consisting of an implantable anti-reflux device and an esophageal measurement tool, has obtained approval from the National Medical Products Administration (NMPA). With the approval of this system, the company's product portfolio has become more comprehensive and diversified.</p>\n<p>The anti-gastroesophageal reflux system is a self-developed surgical device designed for magnetic sphincter augmentation (MSA) procedures to treat gastroesophageal reflux disease (GERD). The MSA procedure aims to enhance the tension of the lower esophageal sphincter (LES) to achieve anti-reflux effects.</p>\n<p>The system works by implanting a device in the functional region of the LES outside the esophagus. The magnetic beads within the implanted device generate magnetic attraction, thereby strengthening the LES tension and restoring its anti-reflux function to treat GERD.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRYOFOCUS-B (06922): Anti-Gastroesophageal Reflux System Receives NMPA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRYOFOCUS-B (06922): Anti-Gastroesophageal Reflux System Receives NMPA Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-16 18:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CRYOFOCUS-B (06922) announced that on December 15, 2025, its anti-gastroesophageal reflux system, consisting of an implantable anti-reflux device and an esophageal measurement tool, has obtained approval from the National Medical Products Administration (NMPA). With the approval of this system, the company's product portfolio has become more comprehensive and diversified.</p>\n<p>The anti-gastroesophageal reflux system is a self-developed surgical device designed for magnetic sphincter augmentation (MSA) procedures to treat gastroesophageal reflux disease (GERD). The MSA procedure aims to enhance the tension of the lower esophageal sphincter (LES) to achieve anti-reflux effects.</p>\n<p>The system works by implanting a device in the functional region of the LES outside the esophagus. The magnetic beads within the implanted device generate magnetic attraction, thereby strengthening the LES tension and restoring its anti-reflux function to treat GERD.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"醫療保健設備","start_time":0,"source_url":"","article_id":"1121699847","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121699847","pubTimestamp":1765880303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CRYOFOCUS-B (06922) announced that on December 15, 2025, its anti-gastroesophageal reflux system, consisting of an implantable anti-reflux device and an esophageal measurement tool, has obtained...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","06922":"康沣生物-B"},"translate_title":"CRYOFOCUS-B(06922)：抗胃食管反流系统获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06922":1},"content_text":"CRYOFOCUS-B (06922) announced that on December 15, 2025, its anti-gastroesophageal reflux system, consisting of an implantable anti-reflux device and an esophageal measurement tool, has obtained approval from the National Medical Products Administration (NMPA). With the approval of this system, the company's product portfolio has become more comprehensive and diversified.\nThe anti-gastroesophageal reflux system is a self-developed surgical device designed for magnetic sphincter augmentation (MSA) procedures to treat gastroesophageal reflux disease (GERD). The MSA procedure aims to enhance the tension of the lower esophageal sphincter (LES) to achieve anti-reflux effects.\nThe system works by implanting a device in the functional region of the LES outside the esophagus. The magnetic beads within the implanted device generate magnetic attraction, thereby strengthening the LES tension and restoring its anti-reflux function to treat GERD.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}